louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01246934: Segment Transport Versus Acute Shortening In The Treatment of Tibial Pseudarthroses With Bone Loss
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: TIBIA PSEUDOARTHROSES
Lead sponsor: Bezmialem Vakif University
Sponsor class: OTHER
First posted: 2010-11-24
Enrollment: 22
Sex: ALL
Minimum age (years): 13
Maximum age (years): 50
Standard ages: CHILD
ADULT
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study the investigators are presenting the advantages as well as the disadvantages of ACUTE SHORTENING AND RELENGTHENINIG VS SEGMENT TRANSPORT methods.


Eligibility criteria: Inclusion Criteria:TIBIA PSEUDOARTHROSES -

Exclusion Criteria:BONE LOSS GREATER THAN 10 CM

-

Primary outcomes:
measure: TREATMENT PERIOD AND COMPLICATION RATE
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Cengiz Sen
Study officials:
References:
citation: Paley D, Sen C, Tetsworth K. Acute Shortening With Subsequent Relengthening Versus Bone Transport In The Treatment Of Tibial Bone Defect, 11th Asami North America Annual Scientific Meeting, February 18-25, Berkeley Ca, 2001
Clinical trial NCT00946634: Ozone Therapy in Endodontic Practice, in Vivo Study
Official title: Phase 4 - Ozone Therapy in Endodontic Practice, in Vivo Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Primary Apical Periodontite
Lead sponsor: University of Sao Paulo
Sponsor class: OTHER
Collaborators: name: Fundação de Amparo à Pesquisa do Estado de São Paulo
First posted: 2009-07-27
Enrollment: 60
Sex: ALL
Minimum age (years): 13
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The ozone therapy has been coming up as a new therapeutic modality. Medicine has been practicing since XIX century and counted great results. It is indicated for the treatment of 260 different pathologies. The researches in Dentistry has showed promising results, indicating a wide spread action in whole dental specialties. The great oxidative power of ozone provides a great antimicrobial effect and it increases the adenosine triphosphate (ATP) synthesis that can be considered as a general improvement of the cell metabolism, which can potentize the repair process. Thus, these facts justify the present study which will assess the increase of speed of apical periodontite repair.


Eligibility criteria: Inclusion Criteria:

* Healthy patients
* Radiographic evidence of apical periodontite
* No previous root canal treatment

Exclusion Criteria:

* Unhealthy patients
* Regular response to sensibility test
* Previous root canal treatment

Primary outcomes:
measure: Acceleration in repair by healing of apical periodontite
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Fundação para o Desenvolvimento Científico e Tecnológico da Odontologia of University of Sao Paulo
state: SP
Study officials:
affiliation: University of Sao Paulo
name: José L Lage-Marques, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01577134: Personal Resources of Elderly People With Multimorbidity
Official title: Personal Resources of Elderly People With Multimorbidity: Fortification of Effective Health Behaviour
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multimorbidity
Keywords: multimorbidity
autonomy
older adults
physical activity
intervention
behavior change
Lead sponsor: German Centre of Gerontology
Sponsor class: OTHER_GOV
Collaborators: name: German Federal Ministry of Education and Research
name: Freie Universität Berlin
First posted: 2012-04-13
Enrollment: 310
Sex: ALL
Minimum age (years): 64
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: PREFER II aims at developing psychological targeted theory- and evidence-based intervention components, which support older people with multiple illnesses in performing more physical activity. Many studies provide evidence for the importance of physical activity as a central mediator of health. This means that determinants of physical activity such as personal resources constitute an ideal target for interventions.

Within PREFER II, particularly positive views on ageing, attitudes, self-efficacy, planning and self-monitoring will be targeted in the interventions. These factors are important both for motivating older people with multiple illnesses to change their health behaviors and to translate such motivation into behavior.


Eligibility criteria: Inclusion Criteria:

* 64 years or older
* community-residing

Exclusion Criteria:

* regularly exercising

Primary outcomes:
measure: Change in physical activity
timeFrame: Baseline, 6 weeks, 10 weeks, 8.5 months, 12 months
Secondary outcomes:
measure: Change in quality of Life
timeFrame: Baseline, 6 weeks, 10 weeks, 8.5 months, 12 months
measure: Change in self-reported perceived autonomy
timeFrame: Baseline, 6 weeks, 10 weeks, 8.5 months, 12 months
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: German Centre of Gerontology
Study officials:
affiliation: German Centre of Gerontology
name: Clemens Tesch-Römer, Prof. Dr.
role: STUDY_CHAIR
affiliation: Freie Universität Berlin
name: Ralf Schwarzer, Prof. Dr.
role: STUDY_CHAIR
References:
Clinical trial NCT03895034: Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes
Official title: A Single Center Exploratory Study to Evaluate the Use of the RxSight Light Adjustable Lens (LAL) and the Light Delivery Device (LDD) to Improve Visual Outcomes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Conditions: Aphakia
Cataract
Keywords: Light Adjustable Lens
Intraocular lens
LAL
Lead sponsor: RxSight, Inc.
Sponsor class: INDUSTRY
First posted: 2019-03-29
Enrollment: 66
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate, for the visual correction of aphakia, whether the RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) can be used to improve visual outcomes after performing adjustments of the LAL with the LDD. This is an exploratory study. No primary effectiveness endpoints will be identified.


Eligibility criteria: Inclusion Criteria:

* Must sign a written Informed Consent form and be willing to undergo cataract surgery for unilateral or bilateral implantation of the RxLAL.
* Between the ages of 40 and 80 inclusive on the day the cataract surgery is performed.
* Study eye must have cataract causing reduction in best corrected distance visual acuity (BCDVA) to a level of 20/32 or worse with or without a glare source.
* Willing and able to comply with the requirements for study specific procedures and visits.

Exclusion Criteria:

* Study eye with pseudoexfoliation.
* Study eye with diabetes with any evidence of retinopathy.
* Study eye with evidence of glaucomatous optic neuropathy.
* Study eye with history of uveitis.
* Study eye with prior history of Intacs, Radial keratotomy (RK), Conductive keratoplasty (CK), Astigmatic keratotomy (AK), Phakic Implantable Collamer Lens (ICL), Corneal Inlay, or with previous pterygium excision unless the pterygium did not extend more than 2mm onto the cornea from the limbus.
* Subjects taking systemic medication that may increase sensitivity to UV light.
* Subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen.
* Study eye with history of ocular herpes simplex virus.
* Study eye with history of a congenital color vision defect

Primary outcomes:
measure: Percent of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/20 or Better
timeFrame: 3 months post op
Secondary outcomes:
Other outcomes:
Locations:
city: Tijuana
country: Mexico
facility: CODET Vision Institute
Study officials:
References:
Clinical trial NCT01634334: Improving Household Air Quality in Homes With Children
Official title: Innovation for Smoke-Free Homes: Real-Time Feedback
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lung Diseases
Asthma
Keywords: Secondhand smoke
Lead sponsor: San Diego State University
Sponsor class: OTHER
First posted: 2012-07-06
Enrollment: 298
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine if real-time feedback (lights/sounds) from small smoke particle monitors and brief coaching will encourage parents to reduce young children's secondhand tobacco smoke exposure in their home.

Detailed description: The purpose of this efficacy study is to test whether children's home secondhand tobacco smoke exposure (measured by cotinine \& nicotine assays, fine particulates and reports of smoking in the home and/or home smoking bans) can be reduced by using custom particle monitors to provide real-time feedback to household residents plus brief advice/praise.

Eligibility criteria: Inclusion Criteria:

* Families with at least one parent or guardian (18 years of age or older),
* Household resident who smokes tobacco,
* Child under fourteen years old exposed to tobacco smoking in the home
* Plans to live in San Diego County for at least three months.

Primary outcomes:
measure: Secondhand Smoke Reduction
timeFrame: Measured from baseline upto 5 months
Secondary outcomes:
measure: Home Smoking Ban
timeFrame: Measured from baseline upto 5 months.
Other outcomes:
Locations:
city: San Diego
country: United States
facility: SDSU - Center for Behavioral Epidemiology and Community Health
state: California
Study officials:
affiliation: SDSU - Center for Behavioral Epidemiology and Community Health
name: Melbourne F Hovell, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hovell MF, Bellettiere J, Liles S, Nguyen B, Berardi V, Johnson C, Matt GE, Malone J, Boman-Davis MC, Quintana PJE, Obayashi S, Chatfield D, Robinson R, Blumberg EJ, Ongkeko WM, Klepeis NE, Hughes SC; Fresh Air Research Group. Randomised controlled trial of real-time feedback and brief coaching to reduce indoor smoking. Tob Control. 2020 Mar;29(2):183-190. doi: 10.1136/tobaccocontrol-2018-054717. Epub 2019 Feb 15.
citation: Hughes SC, Bellettiere J, Nguyen B, Liles S, Klepeis NE, Quintana PJE, Berardi V, Obayashi S, Bradley S, Hofstetter CR, Hovell MF. Randomized Trial to Reduce Air Particle Levels in Homes of Smokers and Children. Am J Prev Med. 2018 Mar;54(3):359-367. doi: 10.1016/j.amepre.2017.10.017. Epub 2018 Jan 2.
Clinical trial NCT02996734: Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment
Official title: Il Tumore a Cellule Giganti Delle estermità
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Giant Cell Tumor of Bone
Keywords: bone tumors
giant cell tumor
treatment
Lead sponsor: Istituto Ortopedico Rizzoli
Sponsor class: OTHER
First posted: 2016-12-19
Enrollment: 412
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with giant cell tumor of bone treated in a single institution

Brief summary: The purpose of this project is to present the outcomes of patients with giant cell tumor of bone (GCTB) who were treated with surgery and/or medical treatment in a single institution.

Detailed description: The investigators retrospectively review patients treated for GCTB of the extremities between 1990 and 2013 in a single institution. We evaluate the recurrence free survival rate after surgical and medical treatment of patients with GCTB of the extremities to determine the influence of the surgical approach, denosumab therapy, local tumor presentation, and demographic factors on the risk of recurrence.

Eligibility criteria: Inclusion Criteria:

* giant cell tumors of the extremities

Exclusion Criteria:

* giant cell tumors of the spine and pelvis

Primary outcomes:
measure: local recurrence rate after surgical and medical treatment
timeFrame: within the first 36 months after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Istituto Ortopedico Rizzoli
name: Davide Donati, MD
role: STUDY_DIRECTOR
References:
citation: Tsukamoto S, Mavrogenis AF, Leone G, Righi A, Akahane M, Tanzi P, Kido A, Honoki K, Tanaka Y, Donati DM, Errani C. Denosumab does not decrease the risk of lung metastases from bone giant cell tumour. Int Orthop. 2019 Feb;43(2):483-489. doi: 10.1007/s00264-018-4085-6. Epub 2018 Aug 11.
Clinical trial NCT00781534: A Clinical Trial of Ginseng in Diabetes
Official title: A Clinical Trial of Ginseng for Glucose Intolerance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Diabetes
Keywords: Health Supplements
Ginseng
Diabetes
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2008-10-29
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: a clinical study of Ginseng its potential affect on diabetes

Detailed description: Comparing three groups (those with \& without normal blood sugar levels) to see if there is any clinically significant change in blood sugar levels in relationship to those taking:

1. ginseng
2. ginsenoside RE (a type of metabolized ginseng)
3. placebo

Eligibility criteria: Inclusion Criteria:

* ages 18-65
* healthy, non-diabetic
* healthy, impaired glucose tolerance/mild diabetes (no medications required)

Exclusion Criteria:

* impaired glucose tolerance (borderline diabetes that requires medications)
* diabetes (requiring medications)
* caffeine sensitivity
* known cardiac, peripheral vascular diseases
* arrhythmias (irregular heart rhythms)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Kenneth S Polonsky, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Reeds DN, Patterson BW, Okunade A, Holloszy JO, Polonsky KS, Klein S. Ginseng and ginsenoside Re do not improve beta-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes. Diabetes Care. 2011 May;34(5):1071-6. doi: 10.2337/dc10-2299. Epub 2011 Mar 16.
Clinical trial NCT02800434: Clinical Evaluation of Bilateral Hand Allograft: Pilot Study of 7 Cases
Official title: Clinical Evaluation of Bilateral Hand Allograft: Pilot Study of 7 Cases
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Amputation
Keywords: allograft
hands
immunosuppression
fMRI
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2016-06-15
Enrollment: 7
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The double amputation of the forearms is a rare handicap that seriously impacts the autonomy and the quality of life of patients, social and familial exclusion, and dependence on third parties for everyday activities.

The management of these patients is nearly exclusively through the use of prostheses. Certain patients refuse this solution, or remain penalized by the absence of sensation, the lack of precision in movements, and body image issues related to the amputation; the double graft of hands and forearms may, in this circumstance, be the only solution.

The objective of this pilot study was designed to evaluate the cerebral plasticity of patients who undergo bilateral hand allograph


Eligibility criteria: Inclusion Criteria:

* double amputated patients
* minimum of 3 months and maximum of 3 years interval between amputation and graft
* adult aged 20 to 40 years
* psychological maturity
* written informed consent

Exclusion Criteria:

* mono amputated patients
* previous history of malignant tumor in remission for less than 5 years,
* malignant tumor
* previous psychiatric history
* American Society of Anesthesiology (ASA) score \>2
* New York Heart Association (NYHA) \>1
* nenal insufficiency
* severe hypertension

Primary outcomes:
measure: fMRI for evaluation of brain plasticity after transplant
timeFrame: 1 year
Secondary outcomes:
measure: Rejection
timeFrame: Every 6 months following graft up to 5 years
measure: Adverse events
timeFrame: 5 years
Other outcomes:
Locations:
city: Lyon
country: France
facility: Service d'Urologie et Chirurgie de la Transplantion
Study officials:
affiliation: Hospices Civils de Lyon - Service d'Urologie et Chirurgie de la Transplantion
name: Lionel BADET
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00374634: Individual Versus Standard Follicle Stimulating Hormone Dose for Controlled Ovarian Stimulation and Insemination
Official title: Individual Versus Standard rFSH Dose for Controlled Ovarian Stimulation and Intrauterine Insemination. A Prospective Randomised Multi Centre Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Infertility
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2006-09-11
Enrollment: 234
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test if recombinant follicle stimulating hormone (rFSH) given in individual doses, according to a nomogram we have constructed based on our results from a previous study, results in more patients maturing 2-3 follicles compared to standard dose.


Eligibility criteria: Inclusion Criteria:

* Age between 25-39 years
* First stimulation with rFSH only
* Indication for intrauterine insemination with standard rFSH starting dose
* Regular menstrual bleeding with a cycle between 21-35 days
* Two ovaries
* Bilateral tuba patency
* Semen analysis must be sufficient for insemination according to the diagnostic analysis.

Exclusion Criteria:

* More than three former stimulated intrauterine insemination cycles

Primary outcomes:
measure: Number of mature follicles in the study and control group.
Secondary outcomes:
measure: Number of cycles where the rFSH dose is changed.
measure: Number of cycles cancelled or converted to in vitro fertilisation.
measure: Pregnancy rate.
timeFrame: October 2008
Other outcomes:
Locations:
city: Copenhagen East
country: Denmark
facility: The Fertility Clinic, dep.4071, Copenhagen University Hospital, Rigshospitalet
Study officials:
affiliation: The Fertility Clinic, dep.4071, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen East, Denmark
name: Anders N Andersen, Professor,MD
role: STUDY_DIRECTOR
References:
citation: la Cour Freiesleben N, Lossl K, Bogstad J, Bredkjaer HE, Toft B, Rosendahl M, Loft A, Bangsboll S, Pinborg A, Nyboe Andersen A. Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study. Hum Reprod. 2009 Oct;24(10):2523-30. doi: 10.1093/humrep/dep239. Epub 2009 Jul 14.
citation: Freiesleben Nl, Rosendahl M, Johannsen TH, Lossl K, Loft A, Bangsboll S, Friis-Hansen L, Pinborg A, Andersen AN. Prospective investigation of serum anti-Mullerian hormone concentration in ovulatory intrauterine insemination patients: a preliminary study. Reprod Biomed Online. 2010 May;20(5):582-7. doi: 10.1016/j.rbmo.2010.02.007. Epub 2010 Feb 12.
Clinical trial NCT06177834: Alisklamp and Dorsal Slit Sleeve Circumcision
Official title: Comparison of Alisklamp and Dorsal Slit Sleeve Circumcision: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Circumcision
Lead sponsor: Necmi Kadıoğlu Hospital
Sponsor class: OTHER
First posted: 2023-12-20
Enrollment: 180
Sex: MALE
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In this study the plan is to compare the circumcision performed with Alisklamp versus Dorsal Slit Sleeve method in terms of age, co-existing health conditions, surgery time, recovery period, tissue edema and bleeding, postoperative infection, wound healing, wound dehiscence, skin tunnel, and overall complications.

Detailed description: The study compares two circumcision techniques in children: the dorsal sleeve slit method and the alisclamp method. The dorsal sleeve slit technique, conducted under local anesthesia for about 20-30 minutes, involves cutting the penile skin dorsally, removing excess skin and prepuce, and suturing with 5/0 vicryl. The alisclamp method, also under local anesthesia, entails retracting the penile skin, placing a clamp, excising excess prepuce, and sending the patient home. The clamp is removed after 48 hours without anesthesia, with the total procedure lasting under 5 minutes. This research assesses these methods based on factors like age, co-existing health conditions, surgery time, recovery period, tissue edema and bleeding, postoperative infection, wound healing, wound dehiscence, skin tunnel, and overall complications.

Eligibility criteria: Inclusion Criteria:

male patients between 0-2 years and 6-18 years

Exclusion Criteria:

2-6 years, several penil chordee, hypospadias, previous penil surgery

Primary outcomes:
measure: Healing time
timeFrame: 2 weeks
measure: infections
timeFrame: 2 weeks
measure: wound dehiscence
timeFrame: 2 weeks
measure: skin tunnel
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Mustafa Azizoğlu
Study officials:
affiliation: Necmi Kadıoğlu State Hospital
name: Mustafa Azizoğlu
role: PRINCIPAL_INVESTIGATOR
References: